Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
30 hedge funds and large institutions have $28.1M invested in Astria Therapeutics in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
99% more capital invested
Capital invested by funds: $14.1M → $28.1M (+$14M)
74% more ownership
Funds ownership: 26.8% → 100.79% (+74%)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
25% more funds holding
Funds holding: 24 → 30 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$16M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$4.12M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.69M |
| 4 |
AC
Armistice Capital
New York
|
+$3.07M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$180K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$107K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$64K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$26.6K |
| 5 |
Bank of New York Mellon
New York
|
-$25K |
ATXS Hedge Fund Activity: Q2 2018 in Review
30 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2018, worth a combined $28.1M — up 99% from $14.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ATXS positions and 6 closed out — a net gain of 6 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $16M. The largest seller was Renaissance Technologies, cutting an estimated $180K.
- 30 institutional investors held Astria Therapeutics (ATXS) as of Q2 2018, up from 24 in Q1 2018.
- Funds reported $28.1M of Astria Therapeutics stock for Q2 2018, up 99% quarter-over-quarter.
- 12 funds opened new Astria Therapeutics positions in Q2 2018 and 6 closed out, a net change of +6 holders.
- The largest Astria Therapeutics buyer in Q2 2018 was Federated Hermes, an estimated $16M added.
- The largest Astria Therapeutics seller in Q2 2018 was Renaissance Technologies, an estimated $180K sold.
Based on aggregated 13F filings for Q2 2018.